Innovative Asthma and COPD drug development programmes from GSK, Boehringer-Ingelheim, Dr Reddys, AstraZeneca, Mylan Pharma

April 04, 2016
Top Quote SMi Group will open its doors to host its 12th annual Asthma and COPD event at Holiday Inn Kensington Forum, London, UK next week. The conference on respiratory diseases has once again attracted a global audience of market leaders and scientific pioneers to explore innovative asthma and COPD drug development programmes. End Quote
  • (1888PressRelease) April 04, 2016 - Speaker line up will include key industry players such as: AstraZeneca, Boehringer Ingelheim, Dr. Reddy's Laboratories, GSK, Mylan Pharma, Novartis and many more.

    Here is what the conference speakers are saying about current developments in asthma and COPD sector:
    Jan Olof Svensson, Principal Scientist, AstraZeneca:
    "Novel, patient centered inhaler devices. More once-daily medications coming up. More focus on patient adherence and patient feedback during device and ad-on development.
    At the event this April I will be speaking about an insight into proper characterisation of inhalation products".

    Nayna Govind, Director for the Development of Generic Inhalation Products, Dr. Reddy's Laboratories:
    "The use of triple therapies in clinical practice has been the step forward in the field. Also the research into use of biotechnology to provide potential therapies for asthma directed against some of the inflammatory mediators thought to be involved in the pathophysiology of the disease..."

    For more information, to review the full agenda or to register please visit the event website at www.asthma-copd.co.uk . For those who are interested in attending, please note that registration will be closing soon.

    Highlights of Asthma & COPD 2016 include:
    •Discuss the challenges for generic inhalation products for EU and US markets
    •Gain insight into scientific aspects of quality regulations in respiratory drug development
    •Review innate lymphocytes (ILC) in COPD
    •Learn about "first in class" inhaled drugs for the treatment of COPD and cystic fibrosis
    •Explore corticosteroid insensitivity in severe asthma
    •Study formulation and process of inhaled products
    •Analyse clinical development of generic

    For delegate enquiries contact Matthew Apps +44 (0) 20 7827 6093 or email mapps ( @ ) smi-online dot co dot uk
    For last minute sponsorship opportunities contact Alia Malick on +44 (0) 20 7827 6168 or email: amalick ( @ ) smi-online dot co dot uk

    12th annual Asthma & COPD conference and exhibition
    11th - 12th April 2016
    London, UK
    Contact e-mail: aserazetdinova ( @ ) smi-online dot co dot uk
    Contact number: +44 (0) 20 7827 6093
    Event Website: www.asthma-copd.co.uk

    About SMi Group:
    Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the worlds most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

    ###
space
space
  • FB Icon Twitter Icon In-Icon
Contact Information
Over Satisfied Users & Approved Press Releases
© Copyright 2005-2024, 1888 Press Release. All Rights Reserved